Adjuvant EGFR-TKIs-based therapy: are we ready?
- PMID: 32953472
- PMCID: PMC7481596
- DOI: 10.21037/tlcr.2020.04.08
Adjuvant EGFR-TKIs-based therapy: are we ready?
Conflict of interest statement
Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr.2020.04.08). The author has no conflicts of interest to declare.
Comment on
-
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14. Transl Lung Cancer Res. 2019. PMID: 32010594 Free PMC article. Review. No abstract available.
References
-
- Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27. 10.1016/S1470-2045(06)70804-X - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous